BrainChild Bio announced September 8 it has secured $116 million in Series A funding to advance a novel CAR-T therapy for one of pediatric oncology's most devastating diagnoses. The financing, led by an undisclosed private family fund and foundation, will bankroll a pivotal trial targeting diffuse intrinsic pontine glioma, a brainstem cancer that kills roughly 300 American children each year, typically within eleven months of diagnosis.
The Seattle and Cambridge-based biotech launched in December 2023 out of Seattle Children's Hospital, where its experimental treatment was born. Now it's betting that BCB-276, a CAR-T therapy administered directly into the cerebrospinal fluid, can rewrite survival odds for a disease with no approved treatments.
The single-arm Phase 2 trial, designated NCT07680439, opened this year at six U.S. pediatric neuro-oncology centers. Patients receive up to fifteen CAR-T doses over seven to eight months through a reservoir-catheter implanted in the brain. The therapy targets B7-H3, a protein BrainChild says appears universally in DIPG tumors.
Federal regulators granted the experimental treatment Breakthrough Therapy designation on April 22, 2025, followed by Regenerative Medicine Advanced Therapy designation on May 15, 2025, and Fast Track designation. More significantly, the FDA agreed during a January meeting to permit a single pivotal trial for approval, an unusual regulatory path. "I think this is going to be one of the first times that the FDA has gotten behind that strategy," said Michael Jensen, the company's founder and chief scientific officer, in an interview.
Jensen knows the CAR-T landscape well. He co-founded Juno Therapeutics, which Celgene acquired in 2018 for $9 billion, and later launched Umoja Biopharma. Chief Executive Steven Brugger previously ran Affinivax, which GlaxoSmithKline bought for up to $3.3 billion in 2022. The company now employs about fifty people.
Preliminary data from a Phase 1 study at Seattle Children's, published in Nature Medicine earlier this year, showed manageable safety and hints of survival benefit. Whether those signals translate into approval hinges on the pivotal trial now underway, which measures overall survival as its primary endpoint.
BrainChild's approach diverges from most CAR-T therapies developed for blood cancers. Instead of infusing engineered immune cells intravenously, the company delivers them directly into the central nervous system through repeat dosing. The locoregional administration, BrainChild says, maximizes local exposure while potentially reducing systemic side effects.
Seattle Children's provided the initial equity funding and, as of last September, held approximately 94% ownership, according to a state health department filing. WRF Capital, the investment arm of Washington Research Foundation, joined as a new investor in the current round, alongside the hospital itself.
The financing will also push BCB-214, a triple-target CAR-T therapy aimed at glioblastoma, toward initial clinical testing planned for 2027. That therapy targets three proteins: EGFR, B7-H3, and IL13Rα2. "We're kids first, but not kids only," Brugger said.
BrainChild faces competition on several fronts. Stanford Medicine researchers led by Crystal Mackall and Michelle Monje have been testing a GD2-targeted CAR-T for related brain tumors, with results published in Nature in 2022 and updated since. City of Hope and Mustang Bio are running Phase 1 trials of IL13Rα2-targeted CAR-T therapies for glioblastoma and leptomeningeal brain tumors.
The regulatory landscape for brain tumor therapies shifted last August when Jazz Pharmaceuticals won accelerated approval for Modeyso in recurrent or progressive H3 K27M-mutant diffuse midline glioma, marking the first systemic therapy cleared for that indication. Outside the U.S., China's drug regulator has approved at least one CAR-T therapy for solid tumors, though the timeline and details remain somewhat murky in public disclosures.
BrainChild received an additional boost in January when ScaleReady, a contract development and manufacturing organization, awarded the company a $300,000 process-development grant to refine its manufacturing approach.
For families facing a DIPG diagnosis, the trial represents something rare: options where none existed before. Whether BrainChild's locoregional delivery strategy proves superior to other approaches remains to be seen, but the FDA's willingness to streamline the approval path suggests regulators recognize the urgency. In a disease measured in months, every trial opens a door that was previously closed.
